AVTE רווח נקי למניה ב-12 החודשים האחרונים Aerovate Therapeutics Inc.

Aerovate Therapeutics (AVTE) develops inhalation therapies to combat pulmonary hypertension, focusing on rare pathologies. The trailing 12-month EPS reflects profit dynamics, with the value holding at -1.70. Patent protection and orphan drug status create barriers for competitors, although failed trials have led to workforce reductions and a speculative business valuation.
פילוחים אנליטיים ודוחות נתונים של חברת Aerovate Therapeutics (AVTE)

Aerovate Therapeutics (AVTE) is stagnating due to the cessation of its primary clinical trials. The current TTM net income per share, equal to -1.70, reflects the trailing twelve-month equity profit adjusted for the number of shares. This metric measures the actual efficiency of capital generation per share. The flat trajectory of the TTM net income per share confirms a lack of commercial growth, and the business's fundamental stability is approaching zero.